中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司全资子公司 通过增资实施股权激励及公司放弃优先认购权 暨关联交易的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思全资子公司通过增资实施股权激励及公司放弃优 先认购权暨关联交易的事项进行了核查，具体情况如下： 一、本次增资概述 （一）本次增资的基本情况 为进一步落实安杰思的发展战略，优化全资子公司杭安医学科技（杭州）有 限公司（以下简称"杭安医学"）的资本结构，同时建立健全杭安医学的长效激 励机制，提升杭安医学的运营及管理效率、可持续发展能力及核心竞争力，吸引 和留住优秀人才，有效地将各方利益结合在一起，实现价值共创、利益共享，促 进员工与杭安医学的共同成长及发展，杭安医学拟通过增资形式引入员工持股平 台杭州鼎亮企业管理合伙企业（有限合伙）（以下简称"杭州鼎亮"）。 本次杭州鼎亮出 ...

中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思 2024 年度募集资金存放与使用情况进行了核查， 具体情况如下： 一、募集资金基本情况 二、募集资金管理情况 1 （一）募集资金管理制度情况 为规范公司募集资金管理和使用，保护投资者权益，安杰思按照《中华人民 共和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》 《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》和《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、 法规和规范性文件的规定，结合公司实际情况，制定了《杭州安杰思医学科技股 份有限公司募集资金管理办法》，对募集资金的存放、使用、项目实施管理、投 资项目的变更及 ...

中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 调整募投项目内部投资结构的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思调整募投项目内部投资结构的事项进行了核查， 具体情况如下： 一、募集资金的基本情况 （一）募投项目内部投资结构调整的具体情况 根据安杰思业务发展规划及募投项目的实际进展情况，为提高募集资金使用 效率，确保募投项目建设稳步推进，安杰思经审慎研究，拟对"营销服务网络升 级建设项目"和"微创医疗器械研发中心项目"的内部投资结构进行调整，募投 项目承诺投资总额不变。该等募投项目内部投资结构调整前后具体情况如下： 1、安杰思拟对"营销服务网络升级建设项目"内部投资结构作出如下调整： 经中国证券监督管理委员会《关于同意杭州安杰思医学科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕481 号）同意注册 ...

一、募集资金的基本情况 经中国证券监督管理委员会《关于同意杭州安杰思医学科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕481 号）同意注册，并经上海证 券交易所同意，安杰思首次向社会公开发行人民币普通股（A 股）股票 1,447.0000 万股，发行价格为每股人民币 125.80 元，募集资金总额为人民币 182,032.60 万 元，扣除发行费用人民币（不含增值税）16,931.32 万元后，实际募集资金净额为 人民币 165,101.28 万元。上述募集资金已于 2023 年 5 月 16 日全部到位，并经天 健会计师事务所（特殊普通合伙）审验，于 2023 年 5 月 17 日出具了《验资报 告》（天健验〔2023〕210 号）。 中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥128,599,967.29, representing a 15.27% increase compared to ¥111,561,373.32 in the same period last year[4]. - Net profit attributable to shareholders was ¥56,248,260.62, up 6.57% from ¥52,781,143.37 year-on-year[4]. - Operating profit for Q1 2025 was ¥66,143,296.06, representing a growth of 8.3% from ¥61,034,409.57 in Q1 2024[18]. - Basic and diluted earnings per share were both ¥0.69, up 6.15% from ¥0.65 in the same period last year[4]. - The total comprehensive income for Q1 2025 was ¥56,329,913.25, compared to ¥52,776,576.47 in Q1 2024, reflecting overall growth[19]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 47.25% to ¥7,531,575.42, down from ¥14,279,053.92 in the previous year[4][7]. - Cash flow from operating activities for Q1 2025 was ¥7,531,575.42, a decrease from ¥14,279,053.92 in Q1 2024[21]. - The company reported a net cash inflow from investment activities of ¥28,565,344.17 in Q1 2025, contrasting with a net outflow of ¥15,131,011.34 in Q1 2024[22]. - The company experienced a net increase in cash and cash equivalents of ¥36,612,548.71 in Q1 2025, reversing a decrease of ¥20,450,446.38 in Q1 2024[22]. - Total cash and cash equivalents at the end of Q1 2025 were ¥1,067,829,933.85, compared to ¥1,934,281,703.88 at the end of Q1 2024[22]. Research and Development - Total R&D investment reached ¥12,992,919.40, an increase of 13.05% compared to ¥11,493,491.83 in the same period last year[5]. - R&D expenditure accounted for 10.10% of operating revenue, a slight decrease from 10.30% in the previous year[5]. - Research and development expenses increased to ¥12,992,919.40 in Q1 2025, up from ¥11,493,491.83 in Q1 2024, indicating a focus on innovation[18]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,556,661,527.87, reflecting a 0.27% increase from ¥2,549,778,243.93 at the end of the previous year[5]. - The company's current assets totaled RMB 1,903,653,588.44, compared to RMB 1,894,390,045.41 at the end of 2024, reflecting a growth of approximately 0.14%[13]. - The company's total liabilities decreased to RMB 102,564,409.63 from RMB 152,666,866.13, indicating a reduction of approximately 32.8%[15]. - The total equity attributable to shareholders rose to RMB 2,454,097,118.24 from RMB 2,397,111,377.80, marking an increase of about 2.4%[15]. - Accounts payable decreased significantly from RMB 63,746,014.03 to RMB 41,518,370.56, a decline of approximately 34.8%[15]. - The company reported a total inventory of RMB 60,922,431.15, up from RMB 56,377,372.06, which is an increase of about 9.6%[13]. - The company’s long-term assets totaled RMB 653,007,939.43, slightly down from RMB 655,388,198.52, a decrease of about 0.2%[14]. Shareholder Information - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12]. - Non-recurring gains and losses totaled ¥7,586,988.87 after tax, with significant contributions from government subsidies and asset disposals[6]. Return on Equity - The weighted average return on equity decreased slightly to 2.32% from 2.37% year-on-year[4].

Financial Performance - The company's operating revenue for 2024 reached ¥636,634,113.59, representing a 25.14% increase compared to ¥508,748,507.24 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥293,393,685.99, a growth of 35.06% from ¥217,238,584.26 in 2023, driven by increased sales volume[26]. - The net cash flow from operating activities increased by 42.61% to ¥315,795,149.98 in 2024, up from ¥221,447,224.50 in 2023, due to rapid revenue growth[26]. - Basic earnings per share for 2024 were ¥3.6414, a 21.66% increase from ¥2.9932 in 2023[24]. - The company's total assets as of the end of 2024 were ¥2,549,778,243.93, reflecting a 9.38% increase from ¥2,331,074,065.19 at the end of 2023[23]. - The company reported a net profit of ¥95,940,901.10 in Q4 2024, contributing to a total annual net profit growth[28]. - The net profit attributable to shareholders for Q3 2024 was ¥72,999,557.15, indicating consistent quarterly growth[28]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of 13.8 RMB per 10 shares, totaling approximately 111.20 million RMB, which represents 48.46% of the net profit attributable to shareholders for 2024[6]. - The total amount for cash dividends and share repurchases is 142.16 million RMB, accounting for 48.46% of the net profit attributable to shareholders[6]. - The company has implemented a share repurchase program amounting to 30.97 million RMB, excluding transaction costs[6]. Research and Development - Research and development expenses accounted for 9.30% of operating revenue in 2024, up from 8.11% in 2023[24]. - The company launched 27 product design improvement projects and has 19 new products under development, alongside 7 pre-research projects during the reporting period[37]. - The company is advancing multiple R&D pipelines, including reusable flexible endoscopes and AI-driven clinical diagnosis products, with several products expected to enter the registration phase in 2025[39]. - The total R&D expenditure for the year amounted to ¥59,209,169.42, representing a 43.53% increase compared to ¥41,251,410.55 in the previous year[73]. - The increase in R&D investment is primarily attributed to the development of auxiliary treatment robots and flexible endoscope products, along with an increase in R&D personnel[74]. Market Expansion and Strategy - The company plans to continue expanding its global market presence, which has been a key driver of revenue growth[25]. - The international market continues to show high growth, contributing significantly to overall revenue increases[35]. - The company is actively pursuing market expansion through the introduction of innovative medical devices, enhancing its competitive edge in the healthcare sector[74]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2025[186]. - The company plans to implement a product development and market sales strategy that emphasizes "sales generation, R&D generation, and exploration generation" to enhance its market position[153]. Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for providing guarantees[9]. - The company has not faced any issues with more than half of the board members being unable to guarantee the authenticity and completeness of the annual report[9]. - The company has established a comprehensive information disclosure management system to ensure timely and accurate reporting of significant operational matters[175]. - The company is committed to maintaining high standards of corporate governance, as reflected in the rigorous processes followed by its various committees[198]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, which can be found in the "Management Discussion and Analysis" section[4]. - The company faced risks related to talent retention and potential technology leaks, which could impact its competitive advantage[100][101]. - The company is closely monitoring macroeconomic conditions and adjusting its strategies to mitigate potential impacts from economic fluctuations and policy changes[97]. - The company is facing intensified market competition domestically, with a trend of decreasing procurement prices due to stricter medical insurance cost control[89]. Product Development and Innovation - The company has developed new features for its devices, including detachable and interchangeable clip devices, enhancing operational safety and reducing procedure time[58]. - The company has introduced innovative technologies in the ERCP field, improving the success rate of cannulation with a new coating guidewire technology[58]. - The company is focusing on integrating AI and machine learning into endoscopic procedures to enhance diagnostic accuracy and improve patient outcomes[140]. - The company aims to maintain high R&D investment, particularly in AI clinical diagnosis and minimally invasive treatment technologies, to enhance product competitiveness[162]. Financial Management - The company’s investment activities resulted in a net cash outflow of 1.13 billion yuan, primarily due to the purchase of structured deposits[104]. - Cash and cash equivalents decreased to ¥1,031,231,385.14, representing 40.44% of total assets, down 47.24% from the previous year due to structural deposit purchases[126]. - The company’s trading financial assets increased significantly to ¥671,221,183.18, accounting for 26.32% of total assets, up 714.40% from ¥82,419,132.42 last year[126]. - The company plans to use idle self-owned funds for cash management and increase the amount of temporarily idle raised funds for cash management[192].

杭州安杰思医学科技股份有限公司 2025 年限制性股票激励计划实施考核管理办法 杭州安杰思医学科技股份有限公司（以下简称"公司"或"本公司"）为了 进一步建立、健全公司长效激励机制，吸引和留住优秀人才，充分调动和发挥公 司员工的工作积极性，有效地将股东利益、公司利益和核心团队个人利益结合在 一起，使各方共同关注公司的长远发展，确保公司发展战略和经营目标的实现， 在充分保障股东利益的前提下，按照收益与贡献对等的原则，公司制定了《杭州 安杰思医学科技股份有限公司2025年限制性股票激励计划（草案）》（以下简称 "股权激励计划"或"本激励计划"）。 为保证本激励计划的顺利进行，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券交易所科 创板股票上市规则》（以下简称"《上市规则》"）《科创板上市公司自律监管 指南第4号——股权激励信息披露》（以下简称"《自律监管指南第4号》"）等 有关法律法规和规范性文件以及《杭州安杰思医学科技股份有限公司章程》（以 下简称"《公司章程》"）等的规定，并结合公司 ...

2024 年度独立董事述职报告 尊敬的公司各位董事: 作为杭州安杰思医学科技股份有限公司(以下简称"公司")的独立董事, 我严格按照《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司独立董事管理办法》 等法律法规,以及《公司章程》和《杭州安杰思医学科技股份有限公司独立董事 制度》等有关规定和要求,本着客观、公正、独立的原则,勤勉尽责、独立履职, 及时通过多种途径了解公司生产经营、财务及公司相关发展情况,准时出席相关 会议,积极发挥独立董事作用,有效地维护公司整体利益和全体股东的合法权益。 现将我作为独立董事 2024 年度履职情况报告如下: 一、独立董事的基本情况 (一) 个人工作履历、专业背景以及兼职情况 夏立安先生,中国国籍,无境外永久居留权,男,1964年9月出生,博士研 究生学历。其主要经历如下:1990年7月至1996年9月，于曲阜师范大学历任 讲师、副教授;1996年 9 月至 1997 年 9 月,于武汉大学法学院任高级访问学者; 1997 年 9 月至 1998 年 9 月，于曲阜师范大学任副教授; 1998 年 9 月至 20 ...

杭州安杰思医学科技股份有限公司 综上，我们同意提名沈梦晖、冯洋为公司第三届董事会独立董事候选人，并 同意将该议案提交公司第二届董事会第十九次会议进行审议。 董事会提名委员会关于第三届董事会独立董事候选人的审核意 杭州安杰思医学科技股份有限公司董事会提名委员会 2025 年 4 月 21 日 见 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》《上市公司独立董事管理办法》及《杭州安杰思医学科技股份有限 公司公司章程》等有关规定，公司第二届董事会提名委员会对第三届董事会独立 董事候选人的任职资格进行了审核并发表审核意见如下: 1、经审阅公司第三届董事会独立董事候选人沈梦晖、冯洋的个人履历等相 关资料，上述独立董事候选人未持有公司股份，与公司其他董事、监事、高级管 理人员以及持股 5%以上股东不存在其他关联关系，不存在《公司法》规定的不 得担任公司的董事的情形;未被中国证监会采取证券市场禁入措施;未被证券交 易所公开认定为不适合担任上市公司董事;未受过中国证监会行政处罚和证券交 易所公开谴责或通报批评;没有因涉嫌犯罪被司法机关立案侦查或者涉嫌违法违 规被中国证监会立案调查等情形:经 ...